CONTACT: Dana Golson
205-996-4015 | email
EDIT: Suggest Edits
Join the GRADE study to help us find the best long-term treatment for people living with type 2 diabetes.
The National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, in collaboration with 37 medical clinics including the University of Alabama at Birmingham (UAB), is conducting a study to determine the best combination drug treatment for type 2 diabetes. People who join the study will all take metformin and be randomly (by chance) assigned to take one additional diabetes drug. The medicines and medication combinations used in GRADE are FDA‑approved and recommended by the American Diabetes Association.
Most people with diabetes need drugs to help control blood sugar. Metformin is the usual first-line drug treatment for diabetes. Eventually, most people treated with metformin need a second drug. The four potential second line treatments we are using in GRADE are recommended by the American Diabetes Association and FDA approved. It is not clear which of the four is best for controlling diabetes over the long term when combined with metformin. Each has advantages and disadvantages. The goal of the GRADE Study is to try to find the best long-term treatment for people living with type 2 diabetes.
You may qualify to participate if you are:
-An adult with diabetes for less than 5 years
-Only taking metformin
-Willing to take a second diabetes drug
-4 visits a year at UAB’s Nutrition Sciences clinic
-Diabetes medications and supplies provided at no cost
-Diabetes care visits and lab tests provided at no cost
-Annual diabetes education
Contact Dana Golson, UAB’s GRADE Study Coordinator at (205) 996-4015 or email her at email@example.com
Miriam Rueger, RN